MX2016011897A - Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. - Google Patents

Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.

Info

Publication number
MX2016011897A
MX2016011897A MX2016011897A MX2016011897A MX2016011897A MX 2016011897 A MX2016011897 A MX 2016011897A MX 2016011897 A MX2016011897 A MX 2016011897A MX 2016011897 A MX2016011897 A MX 2016011897A MX 2016011897 A MX2016011897 A MX 2016011897A
Authority
MX
Mexico
Prior art keywords
compositions
methods
formula
compound
selenoorganic compounds
Prior art date
Application number
MX2016011897A
Other languages
English (en)
Inventor
Power Ronan
Lan Zi-Jian
Yiannikouris Alexandros
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of MX2016011897A publication Critical patent/MX2016011897A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente solicitud se relaciona con composiciones que comprenden compuestos de selenio, tal como 5´-Metilselenoadenosina , Se-Adenosil-L -homocisteína, Gama-glutamil-metilseleno-cisteína, un compuesto de la fórmula (I), fórmula (II), un compuesto de la fórmula (III) y combinaciones de las mismas, y métodos para utilizar la misma en la mejora de la función mitocondrial, o tratar disfunción mitocondrial.
MX2016011897A 2014-03-14 2014-03-14 Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. MX2016011897A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/029542 WO2015137983A1 (en) 2014-03-14 2014-03-14 Compositions of selenoorganic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2016011897A true MX2016011897A (es) 2017-04-27

Family

ID=54072241

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011897A MX2016011897A (es) 2014-03-14 2014-03-14 Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
MX2016011898A MX2016011898A (es) 2014-03-14 2016-09-13 Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016011898A MX2016011898A (es) 2014-03-14 2016-09-13 Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.

Country Status (16)

Country Link
US (3) US10201559B2 (es)
EP (1) EP3116511B1 (es)
JP (2) JP6313479B2 (es)
KR (3) KR102448455B1 (es)
CN (3) CN106456658A (es)
AU (4) AU2014386236B2 (es)
BR (1) BR112016020233B1 (es)
CA (1) CA2940283C (es)
DK (2) DK3116511T3 (es)
HU (2) HUE051713T2 (es)
IL (1) IL247312A0 (es)
MX (2) MX2016011897A (es)
PE (1) PE20211069A1 (es)
PT (1) PT3116511T (es)
RU (2) RU2665135C2 (es)
WO (2) WO2015137983A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016020233B1 (pt) * 2014-03-14 2022-07-19 Alltech Inc. Composições de compostos seleno orgânicos e seus usos
AU2016243516A1 (en) 2015-03-27 2017-11-09 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
KR102054640B1 (ko) * 2015-09-24 2019-12-11 서울대학교산학협력단 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CA3017763A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
RU2765286C2 (ru) * 2017-05-19 2022-01-28 Оллтек, Инк. Фармацевтические агенты, композиции и способы, относящиеся к ним
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
WO2019093699A1 (ko) * 2017-11-09 2019-05-16 서울대학교 산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
KR102083180B1 (ko) 2017-11-09 2020-03-02 서울대학교산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
CN108484690B (zh) * 2018-05-16 2021-04-30 新乡拓新药业股份有限公司 一种1,2,3-三-O-乙酰基-5-脱氧-β-D-核糖的制备方法
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020146263A1 (en) * 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
CN111543641A (zh) * 2020-04-27 2020-08-18 江苏惠利生物科技有限公司 一种提高l-硒-甲基硒代半胱氨酸稳定性以及生物利用率的方法
EP4185306A4 (en) * 2020-07-23 2024-11-06 Purdue Research Foundation NOTCH SIGNAL INHIBITORS FOR THE TREATMENT OF OBESITY AND METABOLIC DISEASES
US12370166B2 (en) 2021-11-03 2025-07-29 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
JP2023076373A (ja) * 2021-11-22 2023-06-01 マルサンアイ株式会社 アミロイドβ凝集抑制剤とこれを含む医薬組成物および飲食品、ネプリライシン産生促進剤およびγ－セクレターゼ産生抑制剤
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用
US12285412B1 (en) 2024-12-27 2025-04-29 Imam Mohammad Ibn Saud Islamic University Organoselenium benzimidazole compounds for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6752981B1 (en) 1999-09-08 2004-06-22 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
BR0016058A (pt) 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato
CA2397203A1 (en) 2000-03-31 2001-10-11 Sandra C. Tobias Phosphoramidate prodrugs
WO2003090691A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
US7214668B2 (en) 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
JP2006151965A (ja) * 2004-10-28 2006-06-15 Mi Tec:Kk セレン含有組成物及びその製法
CA2598821C (en) * 2004-12-31 2011-05-31 Heonjoong Kang Organoselenium containing compounds and their use
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
CA2524551C (en) * 2005-10-14 2014-12-16 Alltech, Inc. Use of selenium yeasts in the treatment of alzheimer's disease
CN102764279B (zh) * 2005-10-14 2015-04-01 全面技术公司 改变细胞功能的方法和组合物
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
CA2650309C (en) * 2006-04-24 2014-08-19 Alltech, Inc. Selenium-containing compositions and use of the same
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
JP2010536892A (ja) * 2007-08-31 2010-12-02 ディーエスエム アイピー アセッツ ビー．ブイ． 化粧的及び／又は皮膚科学的使用のための４−アミジノベンジルアミン
EP2220208A4 (en) * 2007-11-23 2010-12-29 Rappaport Family Inst For Res USE OF HAPTOGLOBIN ENTYPIZATION FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES
CN101289495A (zh) * 2008-05-23 2008-10-22 浙江大学 含硒五肽化合物及其应用
MX387621B (es) * 2009-10-22 2025-03-18 Propanc Pty Ltd Una composicion farmceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica.
JP5510302B2 (ja) * 2010-12-15 2014-06-04 トヨタ紡織株式会社 接続部材、その製造方法及び接続構造体
CN103608006B (zh) * 2011-04-01 2017-07-07 伊亚索梅股份公司 包含n‑乙酰基‑l‑半胱氨酸的组合及其用途
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
US9833486B2 (en) 2013-03-15 2017-12-05 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
BR112016020233B1 (pt) 2014-03-14 2022-07-19 Alltech Inc. Composições de compostos seleno orgânicos e seus usos
US20160000136A1 (en) * 2014-07-02 2016-01-07 Hamilton Beach Brands, Inc. Juice Extractor
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities

Also Published As

Publication number Publication date
MX2016011898A (es) 2018-03-12
CN106822168B (zh) 2020-11-27
NZ723233A (en) 2020-10-30
KR102448455B1 (ko) 2022-09-28
DK3116511T3 (da) 2020-11-23
AU2016222315A1 (en) 2017-03-30
JP2017512828A (ja) 2017-05-25
NZ723402A (en) 2024-11-29
KR20160125989A (ko) 2016-11-01
US20160361338A1 (en) 2016-12-15
RU2016136530A (ru) 2018-03-16
RU2665135C2 (ru) 2018-08-28
AU2019246818B2 (en) 2021-02-25
KR20170032862A (ko) 2017-03-23
WO2015137983A1 (en) 2015-09-17
RU2016136530A3 (es) 2019-11-25
AU2014386236A1 (en) 2016-09-01
CA2940283A1 (en) 2015-09-17
CA2940283C (en) 2021-03-30
PE20211069A1 (es) 2021-06-09
KR102764247B1 (ko) 2025-02-07
AU2016222315B2 (en) 2022-08-04
KR20210104070A (ko) 2021-08-24
BR112016020233A2 (es) 2017-08-15
CN106456658A (zh) 2017-02-22
IL247312A0 (en) 2016-09-29
US20160082033A1 (en) 2016-03-24
BR102016021058A2 (pt) 2017-05-30
EP3116511B1 (en) 2020-08-26
BR112016020233B1 (pt) 2022-07-19
WO2017048253A1 (en) 2017-03-23
CN113694074A (zh) 2021-11-26
CN106822168A (zh) 2017-06-13
JP7009053B2 (ja) 2022-01-25
AU2019246818A1 (en) 2019-10-31
US10201559B2 (en) 2019-02-12
PT3116511T (pt) 2020-11-19
JP6313479B2 (ja) 2018-04-18
JP2017078056A (ja) 2017-04-27
EP3116511A4 (en) 2017-10-18
US9642874B2 (en) 2017-05-09
US20160045533A1 (en) 2016-02-18
DK3144001T3 (da) 2021-11-15
KR102466389B1 (ko) 2022-11-11
AU2022204588A1 (en) 2022-07-21
RU2731383C2 (ru) 2020-09-02
HUE056172T2 (hu) 2022-01-28
AU2014386236B2 (en) 2019-07-11
HUE051713T2 (hu) 2021-03-29
EP3116511A1 (en) 2017-01-18
US10201558B2 (en) 2019-02-12
RU2016133469A (ru) 2018-04-17

Similar Documents

Publication Publication Date Title
MX2016011897A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12019501919A1 (en) Dioxolane analogues of uridine for the treatment of cancer
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
EP4236652A3 (en) Materials for organic electroluminescent devices
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201891251A1 (ru) Бициклические ингибиторы pad4
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201691044A1 (ru) Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил
UA120058C2 (uk) Пестицидні композиції
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
PH12017500836A1 (en) Transdermal formulations
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX386861B (es) Composiciones inhibidoras de nitrificación microencapsuladas.
NZ732402A (en) Nitrification inhibitor compositions and methods for preparing the same
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
EA201791174A1 (ru) Антимикотическое соединение
MX2018016290A (es) Agente antidesgaste.
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists